Hepatotoxicity remains one of the biggest reasons for the attrition of candidate drugs during the later stages of drug development. The cell lines and animal models due to species differences provide limited physiological relevant information and have resulted in ‘silent’ hepatotoxic drugs being introduced into clinical trials, garnering huge financial losses for drug companies through withdrawals and late-stage clinical failures. Therefore, interest in new systems to identify human drug toxicity are high, particularly at the preclinical phase. We have developed a novel ‘MicroLiver’ device that provides bioinspired microfluidic environments to allow spatiotemporal control of various chemical and physical culture conditions that are unavailable with other methods, which in turn allows for the manufacturing of more physiologically relevant drug screening platforms. Our microengineering approach using microfluidic technology is designed to simulate liver structure and function.